LONDON, Oct 28 (Reuters) - Swiss drugmaker Novartis
is exploring options to add more medicines to its
direct to patient platform that is expected to launch in the
U.S. next month, CEO Vas Narasimhan told Reuters in an interview
on Tuesday.
"We're certainly looking to see if we can add other
medicines to the platform, but no concrete plans at the moment,"
Narasimhan said.